Premium
Collaborative Counseling Considerations for Pharmacogenomic Tests
Author(s) -
Zierhut Heather A.,
Campbell Colleen A.,
Mitchell Allison G.,
Lemke Amy A.,
Mills Rachel,
Bishop Jeffrey R.
Publication year - 2017
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1980
Subject(s) - pharmacogenomics , multidisciplinary approach , genetic counseling , genetic testing , service delivery framework , medicine , medical education , service (business) , medical physics , pharmacology , genetics , business , social science , sociology , biology , marketing
Increased use of pharmacogenomic ( PG x) testing in the clinical setting has revealed a number of challenges to providing this service. PG x is an important component of precision medicine that brings together the fields of genetics and clinical pharmacology. A model that incorporates a multidisciplinary approach to implementation and information delivery may be the most beneficial to patients and providers. In this review, translational considerations in the provision of PG x testing and counseling services are described. Specifically, we report on the selection of PG x tests, the provision of patient education and counseling, and examples of PG x service delivery models that incorporate counseling by pharmacists and genetic counselors. Examples of ancillary risks associated with PG x testing, testing of children, and familial implications of testing are reviewed. Through multispecialty partnerships, including genetic counselors and pharmacists, implementation obstacles to PG x testing can be overcome to provide quality precision medicine to patients.